Syngene Utilizes New Innovation in the Manufacturing Value Chain

Contract development and manufacturing organizations (CDMOs) are more critical than ever as the demand for advanced therapies continues to grow.

Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.

Lonza’s new tailored offering leverages the company’s bi-layer capsule manufacturing technology.

Modular and replication strategies are being utilized to meet growing demand for CDMO facilities.

The company officially launched new production suites, a revamp of its development labs, and more at its Thousand Oaks, Calif., cell therapy manufacturing facility.

The company will now include GMP cell-based potency assays at its Cambridge, UK, and San Diego, Calif., sites expanding its early and late phase analytical capabilities.